The Food and Drug Administration named a longtime pharmaceutical executive to run the agency’s drug program. Dr.

Tidmarsh, who has founded and served as CEO of several biotech companies, will lead a crucial FDA division that reviews the ...

The agency also revoked Sarepta's platform technology designation for AAVrh74 Friday and issued a safety communication saying ...

Food and Drug Administration commissioner Marty Makary has chosen former biotech executive George Tidmarsh as the agency’s ...

Kostas Biliouris, BMO Capital Markets biotech analyst, joins CNBC's 'Squawk on the Street' to discuss the latest details on ...

Salmonella can cause serious and potentially fatal infections in young children, the frail or elderly, and others with ...

U.S. Food and Drug Administration commissioner Marty Makary has chosen former biotech executive George Tidmarsh as the ...

By Sriparna Roy and Sneha S K (Reuters) -The U.S. Food and Drug Administration said on Monday it has appointed George ...

The U.S. Food and Drug Administration ( FDA) has placed an immediate clinical hold on Sarepta Therapeutics' investigational ...

U.S. regulators asked Sarepta Therapeutics on Friday to voluntarily halt shipments of its Elevidys gene therapy after a ...

Drugmaker Sarepta Therapeutics says it won’t comply with a request from U.S. regulators to halt all shipments of its gene ...

La Administración de Alimentos y Medicamentos de Estados Unidos (FDA, por sus siglas en inglés) permitirá que la marca de ...